type 2 Diabetes. Non-insulin-dependent diabetes mellitus
Conditions
Interventions
Intervention 1: Intervention group: patients will be treated with Ribes khorassanicum hydro ethanolic extract (1 capsule = 500 mg, every 12 h) for 3 months. Intervention 2: Placebo group: patients wil
Treatment - Drugs
Placebo
Intervention group: patients will be treated with Ribes khorassanicum hydro ethanolic extract (1 capsule = 500 mg, every 12 h) for 3 months.
Placebo group: patients will be treated with placebo (1 capsule = 500 mg, every 12 h) for 3 months.
Sponsors
Vice chancellor for research, Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
35 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Age between 35-60, with 6 month diagnosed diabetes (FBS=126 mg/dL, Blood sugar, 2-h post-prandial = 200 mg/dL and HbA1c = 6.5) and used anti-diabetic drug. Exclusion criteria: Patients with cardiac, renal, and hepatic diseases, patients who had concomitant infections, insulin injection, smoking, pregnancy and breast-feeding, patients with recent (in the last month) and concurrent use of herbal medications, aspirin, anticoagulant drug and any report of probable side effect of this study intervention.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| FBS. Timepoint: Before intervention, 3 month after intervention. Method of measurement: Enzymatic kit.;2-h post-prandial. Timepoint: Before intervention, 3 month after intervention. Method of measurement: Enzymatic kit.;HbA1c. Timepoint: Before intervention, 3 month after intervention. Method of measurement: Enzymatic kit.;Fasting insulin. Timepoint: Before intervention, 3 month after intervention. Method of measurement: ELISA kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Hepatic Enzymes. Timepoint: Before intervention, 3 month after intervention. Method of measurement: Enzymatic kit.;Creatinine. Timepoint: Before intervention, 3 month after intervention. Method of measurement: Enzymatic kit.;Fasting blood levels of lipids. Timepoint: Before intervention, 3 month after intervention. Method of measurement: Enzymatic kit.;Body mass index. Timepoint: Before intervention, 3 month after intervention. Method of measurement: height (cm), weight (kg), BMI (kg/square meters).;Blood pressure. Timepoint: Before intervention, 3 month after intervention. Method of measurement: Sphygmomanometer. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZahra Gholamnezhad
Mashhad University of Medical Sciences
Outcome results
None listed